Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess
long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate
to severe alopecia areata.
Phase
Phase 2/Phase 3
Funding Agency/Sponsor
Industry
Disease
Other
Enrollment Eligibility
Inclusion Criteria:
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Exclusion Criteria:
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
keratosis
- Females who are nursing, pregnant, or planning to become pregnant while in the study,
and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of
study medication